Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 17/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CD69 | Q07108 | 1/20 | 0.36 |
| ▸ | YES1 | P07947 | 1/20 | 0.34 |
| ▸ | FGR | P09769 | 1/20 | 0.34 |
| ▸ | TEC | P42680 | 1/20 | 0.34 |
| ▸ | BMX | P51813 | 1/20 | 0.34 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23080936 | 0.81 | HTR6 (0.38) | BTKHTR6KCNH2TYK2 | |
| SCHEMBL16764187 | 0.80 | HRH3 (0.43) | BTK | |
| SCHEMBL16764188 | 0.80 | HRH3 (0.43) | BTK | |
| SCHEMBL16786047 | 0.79 | HTR6 (0.37) | BTKHTR6 | |
| Hydrochloric Acid SCHEMBL16763471 | 0.78 | BTK (0.36) | BTKHTR6 | |
| Hydrochloric Acid SCHEMBL16763472 | 0.78 | BTK (0.36) | BTKHTR6 | |
| SCHEMBL20752427 | 0.77 | BTK (0.47) | BTKKCNH2CD69YES1FGR | |
| SCHEMBL20365206 | 0.71 | BTK (0.43) | BTKKCNH2CD69 | |
| SCHEMBL25593938 | 0.70 | BTK (0.36) | BTK | |
| SCHEMBL23080928 | 0.68 | HTR2B (0.37) | HTR6TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | BTK 1/4885HTR6 3395/4885KCNH2 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.